These results showed that treatment with SNORA23 and rapamycin in combination effectively inhibited the PI3K/AKT/mTOR-RPS6/4EBP1 cascade and the tumorigenesis of HCC both in vitro and in vivo, providing a promising therapeutic strategy for treatment of HCC. Here, RPS6 is linked to hepatocellular carcinoma.